Avoid common mistakes on your manuscript.
Dear Sirs,
Multiple myeloma (MM) is characterized by the accumulation of monoclonal plasma cells [12], with common nervous system involvement including peripheral neuropathy and epidural compression [2]. In contrast, intraparenchymal lesions and infiltration of cerebrospinal fluid (CSF) and leptomeninges (meningeal myelomatosis) are rare; CSF infiltration occurs in 1% of MM patients [4], which is less common than in solid tumours (1–5%) and much less than in lymphoma and leukaemia (5–15%) [1, 7]. We present a MM patient with progressive and stepwise, multifocal neurological symptoms. Craniospinal MRI was normal, but CSF examination confirmed the diagnosis of meningeal myelomatosis.
A 63-year-old male visited the emergency department with double vision and repetitive short-lasting episodes of light-headedness and headache when standing up without loss of consciousness. Nine months earlier he had been diagnosed with Durie-Salmon stage IIIA (International Scoring System stage 3) IgA-kappa MM, with bone lesions (skull, spine, long bones) and an extramedullary left psoas muscle mass. Three cycles of induction chemotherapy with thalidomide, doxorubicine, and dexamethasone were followed by melphalan with stem cell rescue. Four months later, he experienced a relapse with reoccurrence of the psoas lesion and new extramedullary (paranasal sinuses and paravertebral) lesions, for which lenalidomide, dexamethasone and radiotherapy of the psoas lesion was initiated.
At the time of presentation in the emergency department, just after initiation of lenalidomide and dexamethasone, no abnormalities of ocular motility could be found although the patient still experienced double vision. A mild paresis of the right peroneus muscle, hypoesthesia of the first to third right toes, and absent achilles tendon reflexes were noted. Differential diagnosis was broad (Table 1). Electrocardiography, laboratory investigations and gadolinium-enhanced brain MRI (Fig. 1a1) were normal.
One week later, the double vision and light-headedness had disappeared, but the patient had developed a mild paresis of the right biceps and triceps muscles with normal tendon reflexes. Because of the multifocal neurological deficits, the revised differential diagnosis (Table 1) included cervical epidural MM localization and meningeal myelomatosis. However, CT of the neck and cervical spine MRI were normal. Right arm electromyography revealed signs consistent with a C5 or C6 radiculopathy.
Another week later, the patient developed a slight dysarthria and severe weakness of the left anterior tibial muscle. Lumbar epidural compression, meningeal myelomatosis or infection were considered, but gadolinium-enhanced lumbar spine MRI was normal (Fig. 1a2). However, CSF examination showed 133×106 leucocytes/L and an elevated total protein level of 0.63 g/L; flow cytometry demonstrated 92% monoclonal plasma cells (Fig. 1b, c).
We concluded that the patient’s multifocal neurological abnormalities were due to meningeal myelomatosis. He was treated with biweekly intrathecal methotrexate and prednisone. After two courses, no more plasma cells could be detected in the CSF, CSF leukocyte count (1×106/L) and total protein level (0.34 g/L) normalised and his neurological symptoms had improved. Three months later the patient died from progressive systemic disease. Autopsy confirmed the diagnosis of meningeal myelomatosis.
In this MM patient, the uncommon occurrence of meningeal myelomatosis was associated with negative craniospinal MRI. This patient’s history stresses that, in cases with a high clinical suspicion of meningeal myelomatosis, a normal MRI should be followed by CSF examination.
Symptoms and signs of meningeal myelomatosis are usually multifocal, including non-specific prodromes, cranial nerve neuropathy and radiculopathy (all present in our case) and may vary greatly according to involved structures. Contrast-enhanced MRI is often used to diagnose neoplastic meningitis, but sensitivity is much lower for hematologic malignancies (20–37% for leukaemia and lymphoma) than for solid tumours (85%) [10]. In contrast, MRI was false-negative in only 8% of a group of myelomatous meningitis patients [8, 9].
There is no standardized treatment for meningeal myelomatosis. Treatment options include craniospinal radiation or intrathecal chemotherapy, often accompanied by systemic chemotherapy [2, 8, 11, 13], but survival is generally short [6, 8, 13].
In conclusion, meningeal myelomatosis, although rare, should be considered in MM patients with progressive multifocal neurological deficits, even when MRI is normal. CSF investigation is mandatory in an early stage to prevent delay in diagnosis and treatment.
References
Chamberlain MC (2010) Leptomeningeal metastasis. Curr Opin Oncol 22:627–635
Chamberlain MC, Glantz M (2008) Myelomatous meningitis. Cancer 112:1562–1567
Dennis M, Chu P (2000) A case of meningeal myeloma presenting as obstructive hydrocephalus–a therapeutic challenge. Leuk Lymphoma 40:219–220
Fassas AB, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R, Siegel D, Badros A, Toor A, Zangari M, Morris C, Angtuaco E, Mathew S, Wilson C, Hough A, Harik S, Barlogie B, Tricot G (2002) Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol 117:103–108
Guy J, Mancuso A, Beck R, Moster ML, Sedwick LA, Quisling RG, Rhoton AL Jr, Protzko EE, Schiffman J (1991) Radiation-induced optic neuropathy: a magnetic resonance imaging study. J Neurosurg 74:426–432
Halczuk I, Ilzecka J, Stelmasiak Z (1999) Myelomatous meningitis: a case report. Neurol Neurochir Pol 33:1425–1433
Kesari S, Batchelor TT (2003) Leptomeningeal metastases. Neurol Clin 21:25–66
Nieuwenhuizen L, Biesma DH (2008) Central nervous system myelomatosis: review of the literature. Eur J Haematol 80:1–9
Patriarca F, Zaja F, Silvestri F, Sperotto A, Scalise A, Gigli G, Fanin R (2001) Meningeal and cerebral involvement in multiple myeloma patients. Ann Hematol 80:758–762
Pauls S, Fischer AC, Brambs HJ, Fetscher S, Hoche W and Bommer M (2011) Use of magnetic resonance imaging to detect neoplastic meningitis: Limited use in leukemia and lymphoma but convincing results in solid tumors. Eur J Radiol. doi:10.1016/j.ejrad.2011.02.020
Petersen SL, Wagner A, Gimsing P (1999) Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature. Am J Hematol 62:228–233
Phekoo KJ, Schey SA, Richards MA, Bevan DH, Bell S, Gillett D, Moller H, Consultant Haematologists, South Thames Haematology Specialist Committee (2004) A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 127:299–304
Schluterman KO, Fassas AB, Van Hemert RL, Harik SI (2004) Multiple myeloma invasion of the central nervous system. Arch Neurol 61:1423–1429
Conflict of interest
N. W. C. J. van de Donk received research funding from Celgene.
Open Access
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
van Ginkel, S., Snijders, T.J., van de Donk, N.W.C.J. et al. Progressive neurological deficits in multiple myeloma: meningeal myelomatosis without MRI abnormalities. J Neurol 259, 1231–1233 (2012). https://doi.org/10.1007/s00415-011-6313-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-011-6313-5